Clinical response to ustekinumab for patients with psoriasis was shown to vary by body region, in which lower extremities were identified as the most difficult to treat.
Lower response rates to ustekinumab were found in the lower extremities of patients with psoriasis, according to study findings published in Annals of Dermatology.
As the standard measurement tool used most often to determine treatment efficacy in clinical trials, the psoriasis area severity index (PASI) evaluates 4 body regions (the head/neck, upper limbs, trunk, and lower limbs) and 3 plaque characteristics (erythema, induration/thickness, and scaling).
Although PASI scores are typically reported as a composite measurement and does not account for results for each individual body region, researchers note that clinical responses across these regions may differentially affect patients’ quality of life and impact communication with patients for formulating their treatment plans.
They sought to assess and compare the characteristics of and clinical responses to ustekinumab, a fully human monoclonal antibody that inhibits interleukin (IL)-12 and IL-23 by binding its p40 subunit, across the 4 PASI regions.
A post-hoc analysis of a prospective, observational, and multicenter study conducted in Korea was performed, which recruited patients aged 18 years or older with psoriasis who were given ustekinumab.
In the study, 581 participants (mean [SD] age, 44.2 [13.29] years; mean [SD] disease duration, 11.3 [9.65] years; 67.3% male) provided demographic variables (age, sex, body mass index [BMI], and smoking/ drinking history), disease-related variables (disease duration, age at diagnosis, comorbidity, and medication history), and disease severity variables (body surface area [BSA], PASI, and physician’s global assessment [PGA]). Data on PASI was collected at baseline and after each patient visit.
“For comparisons of effectiveness between the 4 body regions at each post-baseline visit, the assessment of PASI response (PASI 75, 90, and 100) included only patients with PASI sub-scores of greater than or equal to 1 for the body regions at baseline,” noted the study authors.
“Furthermore, determination of the proportion of patients achieving a score of 0 for each of the clinical signs (erythema [redness], infiltration [thickness], and desquamation [scaliness]) assessed in the PASI included only patients with a baseline score of greater than or equal to 2 (moderate to very marked) for each respective body region.”
At baseline, mean [SD] PASI score and BSA percentage was 18.9 [9.69] and 27.8 [17.83], respectively. Regarding prior treatment, 83.8% (n = 487) of the patients had been treated with phototherapy, 84.7% (n = 492) had received oral agents, and 9.6% (n = 56) had previously used biologics.
Findings indicated that among the 4 PASI regions, the correlation between the PASI sub-scores for the upper and lower extremities was the highest (r = 0.680). Comparison of the mean baseline PASI sub-scores revealed significant differences between the body regions, with the highest being for the lower extremities.
Moreover, PASI 90 and PASI 100 scores were the highest for the head and neck region, indicating the highest response rates, while those for the lower extremities were consistently low at all visits.
“Differences in disease burden by region should be considered when evaluating the overall degree of severity of psoriasis in individual patients,” concluded researchers.
Reference
Son SW, Yu DY, Kim Y, et al. Differences in clinical responses to ustekinumab treatment among body regions: Results from a real-world prospective, observational, and multi-center study in Korea. Ann Dermatol. 2022 Feb;34(1):14-21. doi:10.5021/ad.2022.34.1.14
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More